AcquisitionOther
HARROW, INC. acquired TYRVAYA®
Public M&A record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
HARROW, INC. -> TYRVAYA® · $30 million
This acquisition expands Harrow's dry eye portfolio, complementing the Company's flagship VEVYE franchise by addressing dry eye disease with a different underlying mechanism of action.
Open source record (SEC) ↗